Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026

Spero Therapeutics (Nasdaq: SPRO) said it will report fourth quarter and full year 2025 financial results and provide a business update on Thursday, March 26, 2026, after market close.

Rhea-AI Summary

Spero Therapeutics (Nasdaq: SPRO) said it will report fourth quarter and full year 2025 financial results and provide a business update on Thursday, March 26, 2026, after market close. The company noted it does not intend to host a conference call for the release.

Investors should expect a written release and related materials on that date rather than a live audio briefing.

Argus Mar 19 session

+0.41% close to close Open Argus

Details

News Market Reaction – SPRO

In the Mar 19 session, SPRO gained 0.41%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the timing for Spero’s Q4 and full-year 2025 results, following a year marked...

Analysis

This announcement sets the timing for Spero’s Q4 and full-year 2025 results, following a year marked by positive PIVOT-PO Phase 3 data and an NDA resubmission that triggers a $25 million milestone. Prior filings highlighted lower revenue but a narrower net loss and cash of $48.6 million. Investors may focus on tebipenem HBr progress, updated cash runway, and any changes in strategic dependence on this lead asset during the upcoming update.

Key Figures

Milestone payment: $25 million Q3 2025 net loss: $7.4 million Q3 2025 revenue: $5.4 million +5 more

Milestone payment

$25 million

Triggered by GSK tebipenem HBr NDA resubmission, expected Q1 2026

Q3 2025 net loss

$7.4 million

Quarter ended September 30, 2025

Q3 2025 revenue

$5.4 million

Down from $13.5 million year-ago quarter

Cash & equivalents

$48.6 million

Balance at September 30, 2025; management expects runway into 2028

Overall success rate

58.5% vs 60.2%

PIVOT-PO Phase 3 primary endpoint vs IV imipenem-cilastatin

Clinical cure rate

93.5% vs 95.2%

PIVOT-PO Phase 3 clinical cure outcome

Microbiological response

≈60% both arms

PIVOT-PO Phase 3 microbiological outcome

Short interest

2.18%

Reported short interest as a percent of float

Historical Context

5 past events · Latest: Dec 19

5 events

1. Dec 19

   Regulatory milestone

   24h Move

   +1.3%

   GSK resubmitted NDA for tebipenem HBr, triggering a $25M milestone.

2. Nov 28

   Equity compensation

   24h Move

   +3.0%

   Inducement grant of 90,000 RSUs to a new employee under equity plan.

3. Nov 13

   Quarterly earnings

   24h Move

   -1.2%

   Q3 2025 results with positive PIVOT-PO data and reduced net loss.

4. Nov 04

   Earnings date set

   24h Move

   +3.4%

   Announcement of Q3 2025 earnings date and decision not to host a call.

5. Oct 21

   Clinical trial data

   24h Move

   +3.5%

   Phase 3 PIVOT-PO met primary endpoint and was stopped early for efficacy.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, and provide a business update on Thursday, March 26, 2026, after market close. The Company does not intend to host a conference call.

About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need. For more information, visit www.sperotherapeutics.com.

Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
IR@Sperotherapeutics.com

Media Inquiries: 
media@sperotherapeutics.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Spero Therapeutics (SPRO) release its Q4 and full-year 2025 results?

Spero will release Q4 and full-year 2025 results on March 26, 2026 after market close. According to the company, the announcement will include a business update but no live conference call, so materials will be posted following market close.

Will Spero Therapeutics (SPRO) hold a conference call for the March 26, 2026 update?

No, Spero does not intend to host a conference call for the March 26 update. According to the company, results and the business update will be provided in a release and posted materials rather than an audio webcast.

How can investors access Spero Therapeutics (SPRO) financial results on March 26, 2026?

Investors can access results via the company's posted release and investor materials after market close on March 26, 2026. According to the company, no live call will occur, so the investor relations site will host the written information.

What should shareholders expect in Spero Therapeutics' (SPRO) March 26, 2026 business update?

Shareholders should expect a written business update accompanying Q4 and full-year 2025 financial results after market close. According to the company, the update will summarize recent clinical and corporate developments without a live Q&A session.

What time will Spero Therapeutics (SPRO) publish its March 26, 2026 results relative to markets?

Spero will publish its Q4 and full-year 2025 results after market close on March 26, 2026. According to the company, the timing means the release follows U.S. market hours and will be available later that day on its investor site.